Since we first posted on LinkedIn around JANUARY 30, 2020 after analysing the initial data trends and studies being reported, we suspected the projections in morbidity and mortality rates to be higher and indicated this to be a wider public health crisis(beyond China), which had the potential to be a much larger epidemic(pandemic) that could spill over to different countries(especially referencing the travel patterns across the globe). We suspected early on that the adaptive host responses to the virus strain is highly pathogenic and may be spreading un-noticed through passive(and active) carriers. Different populations have different epigenic responses and the incubation time could therefore be anywhere between 2 to 28 days (perhaps even longer), with a high probability of mutations and varying viral loads — all of which we have been trying to confirm through Lab experiments since then. We have also been trying to alert everyone in the Govt. leadership worth any salt and have reached out to the highest level of government authorities.
We have been focused 24*7 developing IP(Intellectual Properties) towards both a Vaccine and an anti-viral Drug/s. However, due to:
a) an anticipated need for an anti-viral Drug/s targeted specifically on the strain to help cure and at the same time offer targeted and effective Prophylaxis,
b) past data indicators on futile Vaccine development efforts in earlier epidemics,
c) the delays in response for testing across multiple labs, and
d) being unsure of the expected results of any preventive vaccinations(including non specific[to the strain] vaccinations) under high moribidity and mortality — especially when there is a significant probability of Mutagenesis),
we have prioritised realising the anti-viral drug component of our IP with our Hit Molecules/Compounds [codenamed Genicscavir(™)] at the highest priority — through a multi-institute collaboration framework through several government labs and institutions.
Brief of Genic AI work on Coronavirus
Genic AI has developed an IP(Intellectual Property) from Computational dataset to Assays Tests upto IND stage wrt SARS-CoV-2, and comparisons (through extensive studies) with Repurposed drugs, which could be useful in turning out a new recombinant/gene vaccine but more importantly, an anti-viral drug cure to address this pandemic, so infected people with COVID-19 conditions can be treated, not just quarantined/managed or experimented through non-specific preventive vaccinations or through other drugs in the market, which may only help temporarily to confine the spread.
We are presently running parallel processes to get ready upto Clinical Trials Phase II and testing several Experimental Assays of our in-silico validations, which involved developing a dataset that includes an extensive system-wide 360 degree analysis and unique data points and biological processes on:
a) the evolutionary mechanisms of the virus
b) analysis of the primary and secondary RNA structures and identify target molecules for RdRp, Proteases and Spike proteins,
c) protein synthesis and analogues,
d) immunological underpinnings at WBC and Lymphocytes and different host response epitopes and proteases,
e) various DMPK profiles
— with a view to realise the Drug at the earliest
Genic AI developed specific markers, sequences and the pointers dataset(an AI/ML output) and the process for anti-viral drug composition based on the analysis above. The analysis is based upon studies/ investigations of the data from SARS(2003), Herpes Zoster, Zika and HIV for brief intervals over a 10+ year period. The Genic AI inhibitors could also have other potential uses on other viruses in the Betacoronavirus family, as well as on HIV. Besides having mapped the morphology and processes, various Design of Experiments (DoE) have been developed for Virology and Host Cells, Protein Synthesis, RNA synthesis, Immunology through Assays at the Bio Science level for various validations through in-vitro, in-vivo tests on Rodents/animal models and then finally on Human trials, depending on the urgency.
At present Genic AI’s plan is to offer the IP to Drug Companies/ Govt. to produce the drug or vaccine upon an IP Licensing arrangement(or Technology Transfer) from Genic AI, while Genic AI will continue to map and help through the Phases I, II, III of the Clinical Trials. In addition to the Computational side which will continue to be run in parallel to the Bio Science experiments, there are several tests at the BSL-3/BSL-4 lab under process on top priority. There are various pieces of the puzzle on various strains that have been put together by Genic AI through its evolving 360 degree system wide analysis, right upto the expedited requirements at Drug approval stage, which can be used for IND applications in multiple countries. Genic AI is working with the infrastructure needed to get the anti-viral (and subsequently the vaccine) in hand and has put together different pieces of infrastructure from different organizations(Public and Private sector) that are spread across geographies, working along several groups at different IITs, other Chemical Labs and Biologics and Virology Labs for use of Biology and Virology Lab facilities, Spectroscopy/Cryo-electron Microscopy facilities, High performance Sequencing machines, HPC Computing facilities, Labs for testing, and engagement with faculties, access to the various libraries for system wide testing and validation purposes.
Genic AI is driven in a mission-mode along with help from Top leadership in the Govt. In India and Leaders from the private sector, and hopes to offer the solution as a response to this unprecedented human crisis. Any help you can provide to expedite the process shall go a long way in finding the rightful place for this endeavour as our collective Innovation response to this unprecedented world crisis.
© 2020 GENIC.AI®